心脏康复对肥胖高血压患者的影响:一项受控试验
1Karadeniz Technical University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Trabzon, Turkey.
Hipertension y riesgo vascular
|November 19, 2023
概括
心脏康复 (CR) 在高血压患者中显著降低了血压. 与非肥胖患者相比,肥胖个体在CR计划后经历了较大的缩血压降低.
科学领域:
- 心脏病学 心脏病学
- 运动生理学 运动生理学
- 公共卫生 公共卫生
背景情况:
- 肥胖和高血压是相关的,心脏康复 (CR) 证明对这两种情况都有效.
- 这项研究调查了CR对肥胖患者和非肥胖高血压患者的影响.
研究的目的:
- 为了比较CR对肥胖和非肥胖高血压患者血压的影响.
- 为了确定CR是否在肥胖高血压个体中更有效.
主要方法:
- 80名高血压患者 (SBP ≥140mmHg和/或DBP ≥90mmHg) 被分为肥胖 (BMI ≥30kg/m2) 和非肥胖 (BMI <30kg/m2) 组.
- 参与者接受了为期10周的以有氧运动为中心的CR计划.
- 静止系统血压 (SBP) 和透气血压 (DBP) 在节目前和后被测量.
主要成果:
- 74名患者完成了这项研究 (37名肥胖者,37名非肥胖者).
- 与基线相比,CR导致所有测量参数的显著改善.
- 肥胖患者的SBP后CR显著减少,比非肥胖患者的SBP显著减少 (p=.003).
- 较高的BMI与较大的SBP降低相关 (r=0.287,p=0.013).
结论:
- 基于运动的CR有效降低肥胖和非肥胖的高血压患者的SBP.
- 与非肥胖人群相比,CR在减轻肥胖高血压个体的SBP方面表现出更高的有效性.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Exercise and Cardiovascular Response
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


